Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BFR-ESS: AI Interruption vs Maintenance in LGESS
NCT03624244Phase 2Recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Jan 2019
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in endometrial stromal sarcoma (ESS) (2 arms), sponsored by Centre Léon Bérard. Primary endpoint: Progression-Free Survival up to 60 months. Started Jan 2019; status: recruiting.
02
Conditions
endometrial stromal sarcoma (ESS)
Beyond the preview
Go deeper on NCT03624244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624244.